The 18 references in paper G. Ignatova L., E. Blinova V., M. Bel'sner S., I. Grebneva V., Г. Игнатова Л., Е. Блинова В., М. Бельснер С., И. Гребнева В. (2016) “Опыт применения селективного ингибитора фосфодиэстеразы-4 рофлумиласта (Даксас) у пациентов с хронической обструктивной болезнью легких и метаболическим синдромом // An experience of therapy of patients with chronic obstructive pulmonary disease and metabolic syndrome with selective phosphodiesterase-4 inhibitor roflumilast” / spz:neicon:pulmonology:y:2016:i:3:p:323-327

1
Федеральные клинические рекомендации по диагнос" тике и лечению хронической обструктивной болезни легких. М.: РРО; 2013.
(check this in PDF content)
2
Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J.2008; 31: 2014–2012.
(check this in PDF content)
3
Loscalzo J. System’s biology and personalized medicine: a network approach to human disease. Proc. Am. Thorac. Soc. 2011; 8: 196–198.
(check this in PDF content)
4
Thomsen M., Dahl M., Lange P. et al. Inflammatory bio" markers and comorbidities in chronic obstructive pul" monary disease.Am. J. Respir. Crit. Care Med.2012; 186: 982–988.
(check this in PDF content)
5
http://www.who.int/respiratory/copd/burden/en/index.html
(check this in PDF content)
6
Sin D.D., Man S.F. Why are patients with COPD at increased risk of cardiovascular diseases? Circulation. 2003; 107 (11): 1514–1519.
(check this in PDF content)
7
Чучалин А.Г. Хроническая обструктивная болезнь лег" ких и сопутствующие заболевания. Русский медицин# ский журнал.2008; 2: 58–64. Таблица 2 Динамика клинико\функциональных показателей на фоне терапии рофлумиластом Table 2 Change in clinical and functional parameters in patients treated with roflumilast Показатель До лечения После леченияр CAT, баллы29,00 ± 3,5124,78 ± 3,17**< 0,005 Число обострений2,58 ± 0,580,95 ± 0,57** ОФВ1, %39,56 ± 1,5745,01 ± 0,57*< 0,05 Примечание: * – p< 0,05; ** – p< 0,005. Note. *,p< 0.05; **,p< 0.005. Таблица 3 Динамика лабораторных показателей на фоне терапии рофлумиластом Table 3 Change in laboratory parameters in patients treated with roflumilast Показатель До лечения После леченияр CAT, баллы29,00 ± 3,5124,78 ± 3,17**< 0,005 СРБ,
(check this in PDF content)
8
Chung K.F. Inflammatory mediators in chronic obstructive pulmonary disease. Curr. Drug Targets Inflamm. Allergy. 2005; 4 (6): 619–625.
(check this in PDF content)
9
Pinto"Plata V.M., Mullerova H., Toso J.F. et al. C"reactive protein in patients with COPD, control smokers and non" smokers. Thorax. 2006; 61: 23–28.
(check this in PDF content)
10
Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. The asso" ciation between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta" analysis. Thorax. 2004; 59: 574–580.
(check this in PDF content)
11
Hole D.J., Watt G.C., Davey"Smith G. et al. Impaired lung function and mortality risk in men and women: findings from Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711–775.
(check this in PDF content)
12
Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study.Am. J. Crit. Care Med. 2002; 166: 333–339.
(check this in PDF content)
13
Sin D.D., Wu. L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a pop" ulation"based study and a systematic review of the literature. Chest. 2005; 127: 1952–1959.
(check this in PDF content)
14
Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholin" ergic bronchodilatator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994; 272: 1497–1505.
(check this in PDF content)
15
Heindl S., Lehnert M., Criee C.P. et al. Marked sympathet" ic activation in patients with chronic respiratory failure. Am.J. Respir. Crit. Care Med.2001; 164: 597–601.
(check this in PDF content)
16
Verma S., Li S.H., Badiwala M.V. et al. Endothelin antago" nism and interleukin"6 inhibition attenuate the pro" atherogenoc effects of C"reactive protein. Circulation. 2002; 105: 1890–1896.
(check this in PDF content)
17
Wellen K.E., Hotamisligil G.S. Inflamation, stress and dia" betes. J. Clin. Invest.2005; 115: 1111–1119.
(check this in PDF content)
18
Boswell"Smith V., Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD"focus on rof" lumilast. Int. J. Chron. Obstruct. Pulm. Dis. 2007; 2 (2): 121–129. Поступила 13.04.16
(check this in PDF content)